Research programme: cell based therapeutics - Propagenix

Drug Profile

Research programme: cell based therapeutics - Propagenix

Latest Information Update: 03 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Propagenix
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Burns; Respiratory tract disorders; Type 1 diabetes mellitus

Most Recent Events

  • 21 Jun 2017 Cell based therapeutics - Propagenix is available for licensing as of 21 Jun 2017. http://www.propagenix.com/
  • 21 Jun 2017 Propagenix in-licenses Conditional Reprogramming technology from Georgetown University prior to June 2017
  • 21 Jun 2017 Propagenix receives SBIR grant from the National Institute of Diabetes and Digestive and Kidney Diseases for development of cell therapies in Type-1 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top